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usage would be needed to identify the reasons and desired out-
comes for the use of these agents. This would also potentially
derive initiatives that might help rationalise the prescription of
these agents.
PCV33
COST ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM
FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATION
Grauer DW, Karpinski TA
1The University of Kansas, Kansas City, KS, USA
OBJECTIVE: Clinical trials have demonstrated moderate thera-
peutic efﬁcacy for orlistat and sibutramine, with patients losing
between 5–10% of initial body weight. Due to the cost of orlis-
tat and sibutramine and moderate efﬁcacy, Kansas Medicaid
chose to use prior authorization to control expenditures on anti-
obesity agents. The objective of this study was to determine if
differences exist in cost and effect between patients who received
PA approval for anti-obesity therapy and those who did not.
METHODS: A retrospective, cohort study was designed in
which patients were divided into those that received PA approval
for sibutramine or orlistat and those that did not. The payer per-
spective was used in this study. Cost data included the total direct
costs incurred by the Medicaid program including medications,
physician ofﬁce visits, hospital admissions, and administrative
costs of the PA program. Effectiveness therapy was measured by
the probability of patients achieving greater than 5% loss of
initial weight. Independent sample t-tests were used to determine
if differences exist between mean costs and effectiveness between
the alternatives. RESULTS: Patients who received PA approval
for orlistat/sibutramine incurred $16,730 ± $20,185 in average
total costs over the study time period compared to $12,527 ±
$18,702 for patients who did not (p = 0.02). Average initial
weights and BMIs for patients who received drug therapy were
286 pounds and 43.4kg/m2 respectively, while patients who
didn’t had average initial weights of 255 pounds and BMI of
38.9kg/m2. Patients who received anti-obesity therapy met the
effectiveness goal 33% of the time, compared to 5% of the time
for a patient who didn’t (p < 0.001). CONCLUSION: The
average cost per Medicaid beneﬁciary was $4203 higher for
those patients who received prior authorization approval for
anti-obesity therapy compared to those who did not. However,
patients also had a signiﬁcantly higher probability of losing
weight.
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QUALITY OF LIFE FROM THE MINNESOTA LIVING WITH
HEART FAILURE QUESTIONNAIRE FOLLOWING AORTIC
VALVE REPLACEMENT SURGERY
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OBJECTIVE: Quality of Life instruments may be generic or
more disease speciﬁc. We were interested in disease speciﬁc
quality of life in patients following aortic valve replacement.
METHODS: We surveyed 743 patients following aortic valve
replacement surgery. The survey instruments were the SF-36 and
the Minnesota Living with Heart Failure Questionnaires.
MLwHF scores are computed by adding scores ranging from 
0 to 5 on 21 questions, yielding total summary scores of 0 to
105 with higher scores indicating poorer quality of life. All
patients were also part of an adult cardiac database that included
prospectively collected information on demographics, diagnosis
and surgical course. One-way analysis of variance (ANOVA)
tests were used to compare continuous demographic, pre-
operative, operative, and post-operative variables, and MLwHF
scores across different valve types. RESULTS: Three hundred
twenty-nine patients (43%) returned surveys. There were no dif-
ferences in age, gender or valve type received between respon-
ders and non-responders. Of the respondents, 226 were male and
103 were female. The average age was 61.8 (standard deviation
= 13.9, range 15 to 90). The majority of patients [222 (67.48%)]
received the Medtronic Freestyle stentless bioprosthetic valve, 16
(4.86%) received stented bioprosthetic valves, 56 (17.02%)
received mechanical valves, and 13 (3.95%) received homo-
grafts. The MLwHF found homograft recipients to have on
average poorer QoL (as reﬂected by higher MLwHF scores), but
these differences were not signiﬁcant. No signiﬁcant differences
were seen in MLwHF scores across valve types. Patient Mean &
Standard Deviation scores for respective categories: Physical
10.45, 10.43; Emotional 5.04, 6.23; Total 23.28, 22.71. CON-
CLUSIONS: Our study suggests that 5 to 10 years after AVR no
single valve type has a clear QoL advantage and conﬁrms pre-
vious reports that age-matched population QoL norms can be
achieved in many domains. Postulated advantages and dis-
advantages of stentless valves did not seem to have any net effect
on QoL.
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VALIDATION OF THE EQ-5D QUESTIONNAIRE IN PATIENTS
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OBJECTIVE: To analyze the construct validity, criterion valid-
ity, and the acceptance and understanding of the EQ-5D in
patients with acute coronary syndromes (ACS). METHODS: All
ACS-diagnosed patients discharged from a university-afﬁliated
hospital during a 3-year period were mailed a questionnaire that
included the EQ-5D and the SF-8. The EQ-5D includes a 100-
point visual analogue scale (VAS) to measure self-reported
current health-state and ﬁve items measuring mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression. Also
included were disease severity measures [Duke Activity Status
Index (DASI), cardiac symptom count (SC), patient-perceived
cardiac disease severity], comorbidity measures (Charlson
comorbidity index, total medication count), and other demo-
graphic and disease-related items. RESULTS: Of 1217 patients,
490 (40.3%) responded. Patients averaged 65.2 (± 11.3) years
of age; 71.0% male; 91.9% Caucasian; 64.3% history of MI.
Acceptance and understanding appeared high with only
0.2%–0.4% of EQ-5D items and 8% of the VAS unanswered.
Correlations between the VAS score and DASI/SC/perceived
severity were rs = 0.741/rs = -0.615/rs = -0.455 (all p < 0.0001).
Levels of responses to EQ-5D items and the VAS score were sig-
niﬁcantly better for patients with very mild/mild perceived
disease severity compared to severe/very severe, and for patients
with a DASI ≥ 18 compared to a DASI < 18. VAS score and 
SF-8 subscale score correlation coefﬁcients ranged from
0.526–0.764 (all p < 0.0001). Signiﬁcant differences were
observed between the response level of individual EQ-5D items
and scores of comparable SF-8 subscales. The nine most common
health states were identiﬁed based on the ﬁve EQ-5D item scores.
As health status diminished there was a decline in the VAS, DASI
and satisfaction with current health state, and an increase in the
perceived severity, comorbidity score, SC, and medication count.
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CONCLUSIONS: The EQ-5D was easily understood and
accepted by this cohort of patients with ACS and can serve as a
valid measure of health-related quality of life in ACS population-
based studies.
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THE IMPACT OF ACEI RELATED COUGH:A SURVEY OF
AUSTRALIAN PATIENTS
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OBJECTIVES: Cough is a widely recognised adverse effect of
Angiotensin-converting enzyme inhibitors (ACEI) and has been
linked to poor medication compliance and potentially poorer
quality of life (QoL). Clinically, AIIRAs (Angiotensin II receptor
antagonists) have been shown to reduce the occurrence of cough
relative to ACEIs. This study was designed to determine the
impact of cough on patients’ QoL by using generic and cough-
speciﬁc QoL measures and contingent valuation (CV) method-
ology. METHODS: Ninety-one patients currently on ACEIs and
48 patients switched from ACEIs to AIIRAs were recruited from
across Australia. Both groups were asked to complete the World
Health Organisation Quality of Life questionnaire (brief version)
(WHOQoL-Bref) and to answer general questions on QoL,
health and demographics. Those on ACEIs also completed the
Cough-speciﬁc Quality of Life Questionnaire (CQLQ). A CV
question, which gave the participants the choice between an
ACEI and AIIRA level of cough, was also asked. The CV health
states were based on clinical trial data. RESULTS: Respondents
ranged in age from 38–81 years (mean = 58.4 years) in the ACEI
group, and 31–82 years (mean = 55.6 years) in the AIIRA group.
A signiﬁcant relationship between cough severity and QoL
existed for the CQLQ (p = 0.003) and the WHOQoL-Bref (p =
0.025) in the ACEI group. Cough severity was signiﬁcantly
related to difﬁculty of sleeping (p = 0.009), being self-conscious
(p = 0.015), and exhaustion (p = 0.002). The CV analysis for the
AIIRA scenario yielded a mean willingness-to-pay of AUS$16.80
per month for those on ACEIs and AUS$16.20 per month for
those on AIIRAs. CONCLUSION: Overall, the results from this
study illustrate the impact that ACEI-induced cough has on
quality of life. Both patient groups were willing to pay over
AUS$16 per month to experience effective hypertension control
associated with a lower risk of experiencing cough. This suggests
that the impact of cough on QoL may be more than previously
considered and should be considered when selecting anti-
hypertensive treatment.
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HEALTH-RELATED QUALITY OF LIFE OF PATIENTS MAKING
AN ATTEMPT AT SMOKING CESSATION
Erickson SR,Thomas LA, Blitz SG
University of Michigan, Ann Arbor, MI, USA
OBJECTIVE: To assess the acute effects of smoking cessation on
health-related quality of life (HQL). METHODS: Question-
naires were mailed to patients enrolled in a smoking-cessation
program just prior to quit date (T1) and 1-week post-quit (T2).
HQL was assessed by the Smoking Cessation Quality of Life
Questionnaire (SCQoLQ). It contains 5 cessation-targeted scales:
social interactions, self-control, sleep, cognitive-functioning, and
anxiety. The SF-36 is included as a generic core. Other data
included patient demographics, duration of smoking, Fagerstrom
scale, and smoking status at T2. Student’s t-test for paired data
was used to compare the T1–T2 HQL scores. Student’s t-test for
independent samples compared the HQL of a higher addiction
(HA) group (Fagerstrom > 6) to a lower addiction (LA) group
(Fagerstrom < = 6). RESULTS: Respondents (n = 34, 12 in HA-
group, 22 in LA-group) averaged 48.6 (+12.0) years of age and
were primarily Caucasian (97%) and female (72.2%). The mean
Fagerstrom score was 5.0 (+2.3). Overall, one week into cessa-
tion (T1 to T2) there was signiﬁcant worsening in SCQoLQ
anxiety (71.5 + 25.1 to 61.1 + 26.0, p = 0.04) and cognitive-
functioning (72.2 + 20.4 to 61.3 + 23.9, p = 0.02) scores and
improved self-control (46.5 + 22.2 to 5.1 + 18.5, p = 0.001) and
SF-36 general health (65.2 + 18.4 to 70.5+16.9, p = 0.01). At
T1, all LA-group HQL scores were higher than HA-group scores,
signiﬁcantly for sleep, cognitive-functioning, anxiety, and SF-36
role-emotional and mental-health. Between T1 and T2 there was
signiﬁcant decline in sleep, cognitive-function, and anxiety and
improved self-control in the LA-group; the HA-group had sig-
niﬁcant improvement in self-control and SF-36 general-health,
but no signiﬁcant changes in other scores. All SCQoLQ scores
at T2 for LA were higher than either the T1 or T2 SCQoLQ
scores for the HA. CONCLUSIONS: Generally, HQL changes
one-week into a smoking cessation attempt. Smokers with higher
addiction have lower HQL when they begin their cessation
attempt, while smokers with lower addiction have greater change
in their HQL.
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OBJECTIVES: 1) To determine the prevalence of depression
symptoms and to describe antidepressant treatment in a popu-
lation with a history of ACS, and 2) To describe the relationship
of depression treatment adequacy and health-related quality of
life (HRQL) controlling for patient, treatment and disease char-
acteristics. METHODS: All ACS-diagnosed patients discharged
from a university-afﬁliated hospital during a 3-year period were
mailed a survey that included the SF-8, EQ-5D and other self-
reported measures of disease and treatment (e.g. physical func-
tioning, comorbidity, medication compliance, perceived cardiac
severity). Patients were categorized based on self-report of
depressive symptoms and antidepressant medication. Adjusted
mean HRQL measures were determined by least square mean
analysis controlling for independent variables. RESULTS: Of
1217 patients, 490 (40.3%) responded. Respondents averaged
65.2 (± 11.3) years of age; 71% male; 92% Caucasian; 64% with
MI history; 17% had their most recent cardiac event within 6
months. No depressive symptoms and no depression treatment
(without depression) were reported by 59.8%; 27.6% reported
untreated depressive symptoms (untreated); 8.6% reported
depressive symptoms and antidepressant medication (under-
treated); and 4.1% reported no symptoms and antidepressant
medication (adequately treated). Adjusted mean SF-8 Mental
Component Summary (MCS-8) scores were 52.8, 52.5, 42.8, and
40.2 for patients without depression, adequately treated,
untreated, and undertreated respectively (p < 0.0001 for all 
pairwise comparisons except for patients without depression vs.
adequately treated and untreated vs. undertreated). The only
other signiﬁcant pairwise HRQL comparison was between the
adjusted mean general health VAS scores for nondepressed and
